$BEONE MEDICINES (06160.HK)$ In 2Q22A, the company achieved revenue of 340 million US dollars (up 127.7% year-over-year and 11.4% quarter-over-quarter), surpassing consensus estimates by 3.7%. Of this, total product revenue was 300 million US dollars (up 119.7% year-over-year and 16.4% quarter-over-quarter), while collaboration revenue reached 37.06 million US dollars (up 266.0% year-over-year but down 17.7% quarter-over-quarter).
Detailed product revenue:
1) Global sales of the BTK inhibitor zanubrutinib in 2Q22A were 130 million US dollars (up 203.5% year-over-year and 23.3% quarter-over-quarter);
2) Revenue from the PD-1 antibody tislelizumab in 2Q22A was 100 million US dollars (up 203.5% year-over-year and 23.3% quarter-over-quarter). According to Eli Lilly and Co (LLY.US), competing product sintilimab generated revenue of 74 million US dollars in 2Q22A (down 29.5% year-over-year and 13.0% quarter-over-quarter);
3) Products licensed from Amgen (AMGN.US) for commercialization in China, including Prolia (denosumab injection), Blincyto (blinatumomab), and Kyprolis (carfilzomib, a proteasome inhibitor), collectively generated revenue of 29.5 million US dollars in 2Q22A (up 793.9% year-over-year and 16.4% quarter-over-quarter), with Blincyto and Kyprolis launched in China in August 2021 and January 2022, respectively.
4) Products licensed from Celgene for...